PCRX - Pacira down 25% as FDA approves generic version of Exparel
2024-07-02 10:06:34 ET
More on Pacira BioSciences
- Pacira BioSciences announces pricing of convertible senior notes due 2029
- Pacira Biosciences announces proposed offering of $250M aggregate principal amount of convertible senior notes
- Pacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Pacira BioSciences